Imaginostics

Imaginostics is a medical imaging diagnostics company developing QUTE-CE MRI (Quantitative Ultra-short Time-to-Echo Contrast-Enhanced magnetic resonance imaging), a technique that turns standard MRI scanners into quantitative instruments for measuring blood vessels in the brain. Its software produces per-patient maps of microvascular structure, vasodilatory function, and blood-brain-barrier leakage from a single scan on existing hardware, using a ferumoxytol-class contrast agent instead of gadolinium. The lead indication is early detection and stratification of Alzheimer's disease and related dementias, with a pivotal clinical study run at Brigham and Women's Hospital in Boston. The company was founded in July 2018 by Valerie Gharagouzloo and Dr. Codi Amir Gharagouzloo, and received FDA Breakthrough Device Designation in October 2024.

The platform is software on top of MRI scanners hospitals already own - no new hardware - and it avoids gadolinium, which makes it usable in chronic kidney disease patients who are excluded from contrast MRI today. Its vascular biomarkers are claimed to surface Alzheimer's-related changes long before symptom onset, and it carries FDA Breakthrough Device Designation plus NIH and Alzheimer's Drug Discovery Foundation backing.